866323-86-6

Basic information

• Product Name: 2-Propenoic acid, 3-[3-[(phenylaMino)sulfonyl]phenyl]-, Methyl ester, (2E)-
• Synonyms: 2-Propenoic acid, 3-[3-[(phenylaMino)sulfonyl]phenyl]-, Methyl ester, (2E)-;(E)-Methyl 3-(3-(N-phenylsulfaMoyl)phenyl)acrylate;2-Propenoic acid, 3-[3-[(phenylaMino)sulfonyl]phenyl]-, Methyl ester, (2E)- (E)-Methyl 3-(3-(N-phenylsulfaMoyl)phenyl)acrylate;Methyl (2E)-3-(3-[(phenylaMino)sulfonyl]phenyl)prop-2-enoate;Belinostat Impurity D;(E)-3-(3-phenylsulfamoyl-phenyl)-acrylic acid methyl ester
• CAS NO: 866323-86-6
• Molecular Formula: C₁₆H₁₅NO₄S
• Molecular Weight: 317.3596
• Mol File: 866323-86-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Propenoic acid, 3-[3-[(phenylaMino)sulfonyl]phenyl]-, Methyl ester, (2E)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propenoic acid, 3-[3-[(phenylaMino)sulfonyl]phenyl]-, Methyl ester, (2E)-(866323-86-6)
• EPA Substance Registry System: 2-Propenoic acid, 3-[3-[(phenylaMino)sulfonyl]phenyl]-, Methyl ester, (2E)-(866323-86-6)

Safety Data

• Hazardous Substances Data: 866323-86-6(Hazardous Substances Data)

Usage

General Description

The chemical "2-Propenoic acid, 3-[3-[(phenylaMino)sulfonyl]phenyl]-, Methyl ester, (2E)-" is a compound commonly known as the methyl ester of 3-(3-aminosulfonylphenyl)acrylic acid. It is primarily used in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceuticals and as a raw material for the production of other organic compounds. This chemical is also used in research and development for its potential medicinal properties and is currently being studied for its anti-inflammatory and anti-cancer properties. It is important to handle this chemical with care, as it can pose health risks if not used properly.

Upstream product

• 610801-83-7 methyl (2E)-3-[3-(chlorosulfonyl)phenyl]prop-2-enoate 
• 62-53-3 aniline 
• 2905-24-0 3-Bromobenzenesulfonyl chloride 
• 292638-85-8 acrylic acid methyl ester 
• 166338-06-3 N-phenyl-3-bromo-benzenesulfonamide 
• 659-04-1 methyl 3-nitrocinnamate 
• 99-61-6 3-nitro-benzaldehyde 
• 58186-45-1 3-(3-amino-phenyl)-acrylic acid methyl ester 
• 100-52-7 benzaldehyde 

Downstream Products

• 866323-14-0 belinostat 
• 866323-87-7 (2E)-3-{3-[(phenylamino)sulfonyl]phenyl}prop-2-enoic acid 

Relevant articles and documents

COMPOUNDS AND METHODS FOR TREATING CANCER

Substituted cinnamamide compounds and analogs, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or ameliorate cancer are provided.

POLYMORPHIC FORMS OF BELINOSTAT AND PROCESSES FOR PREPARATION THEREOF

The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.

Novel sulfonamide derivatives as inhibitors of histone deacetylase

Inhibition of the enzyme histone deacetylase (HDAC) is emerging as a novel approach to the treatment of cancer. A series of novel sulfonamide derivatives were synthesized and evaluated for their ability to inhibit human HDAC. Compounds were identified which are potent enzyme inhibitors, with IC 50 values in the low nanomolar range against enzyme obtained from HeLa cell extracts, and with antiproliferative effects in cell culture. Extensive characterization of the structure - activity relationships of this series identified key requirements for activity. These include the direction of the sulfonamide bond and substitution patterns on the central phenyl ring. The alkyl spacer between the aromatic head group and the sulfonamide functionality also influenced the HDAC inhibitory activity. One of these compounds, m11.1, also designated PXD101, has entered clinical trials for solid tumors and haematological malignancies.